Last reviewed · How we verify
CRN00808
At a glance
| Generic name | CRN00808 |
|---|---|
| Sponsor | Crinetics Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome (PHASE2)
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) (PHASE3)
- A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) (PHASE2)
- An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) (PHASE2)
- Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CRN00808 CI brief — competitive landscape report
- CRN00808 updates RSS · CI watch RSS
- Crinetics Pharmaceuticals Inc. portfolio CI